Genomic landscape of advanced prostate cancer patients with versus mutations as detected by comprehensive genomic profiling of cell-free DNA.

-mutated prostate cancer has been shown to be less responsive to poly (ADP-ribose) polymerase (PARP) inhibitors as compared to -mutated prostate cancer. The reason for this differential response is not clear. We hypothesized this differential sensitivity to PARP inhibitors may be explained by distinct genomic landscapes of versus co-segregating genes.